These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10684207)

  • 1. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
    Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM
    Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M; Frohlich J
    Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hidden effects of antihypertensive and lipid-lowering agents on the prevention and regression of atherogenesis: new management strategies.
    Weinberg MS
    R I Med; 1995 Mar; 78(3):78-81. PubMed ID: 7734758
    [No Abstract]   [Full Text] [Related]  

  • 4. [Atherosclerosis: some topical issues of pathogenesis, diagnosis, treatment and prevention].
    Karpov RS; Dudko VA
    Klin Med (Mosk); 1999; 77(12):9-13. PubMed ID: 10684207
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of lipemia-lowering agents in the secondary prevention of myocardial infarct].
    Tullio D
    Clin Ter; 1986 Feb; 116(3):221-35. PubMed ID: 3516543
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP; Krist A
    J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
    [No Abstract]   [Full Text] [Related]  

  • 7. Dyslipidemia and coronary heart disease: management issues from Indian perspective.
    Gambhir DS; Gambhir JK; Sudha R
    Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772
    [No Abstract]   [Full Text] [Related]  

  • 8. AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis.
    Jellinger PS; Dickey RA; Ganda OP; Mehta AE; Nguyen TT; Rodbard HW; Seibel JA; Shepherd MD; Smith DA;
    Endocr Pract; 2000; 6(2):162-213. PubMed ID: 11428356
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipids and their role in coronary heart disease: what they do and how to manage them.
    Pradka LR
    Nurs Clin North Am; 2000 Dec; 35(4):981-91. PubMed ID: 11072283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype.
    Twickler TB; Dallinga-Thie GM; Cohn JS; Chapman MJ
    Circulation; 2004 Apr; 109(16):1918-25. PubMed ID: 15117861
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.